Market Overview

CURE® Magazine Releases Its Rare Cancers Specialty Issue


The issue highlights new ways to attack cancer of the eye and
features two patients sharing their journeys with uveal melanoma

CURE® magazine, the nation's leading consumer digital
and print media enterprise focused on patients with cancer, published
its most recent Rare Cancers issue, announced Michael J. Hennessy Jr.,
president of MJH Associates Inc., parent company of CURE® magazine.

In making the announcement, Michael J. Hennessy, Jr said, "Our Rare
Cancers issue hits close to home, as we are the leading resource for
cancer updates, research and education within the cancer community. It
is our mission to continue our efforts in providing the most up-to-date
research and studies to cancer patients, survivors and their caregivers."

Although the oncology field continues to advance in many ways, studying
a rare cancer — defined by the American Cancer Society as fewer than six
cases per 100,000 people each year — presents a challenge due to the
rarity of these diseases.

In this issue, CURE® focuses its cover story, Advances
and Combinations Raise Sights on Uveal Melanoma, on the clinical trials
that seek to discover new ways to attack cancer of the eye, limit
metastasis and prevent recurrence of the disease. Two patients share
their very different journeys with uveal melanoma — one woman developing
metastasis to her liver and brain — and how they are doing today.

Also in this issue, CURE® features:

  • Turning the Tide. Innovations in drug development, surgery,
    radiation and clinical trials have investigators hard at work in
  • Waldenstrom Macroglobulinemia: The Discovery and What Lies Ahead.
    This incurable rare cancer of the lymphatic system has seen
    improvements, but what is the best strategy for treating patients with
    the disease?
  • Training Through Treatments: Pro Runner Doesn't Let Rare Cancer
    Slow Her Down.
    After receiving a diagnosis of adenoid cystic
    carcinoma, Gabriele Grunewald wanted to help others and founded Brave
    Like Gabe.

In addition, the magazine offers news and updates within the rare cancer
space, from a Food and Drug approval in thyroid cancer to clinical
trials in pediatric cancers and new targeted therapies for a mantle cell
lymphoma prognosis.

To read more from the Rare
Cancers Special Issue
, visit

About CURE Media Group

CURE Media Group is the leading resource for cancer updates, research
and education. It combines a full suite of media products, including its
industry-leading website,; innovative video programs, such
as CURE Connections®; a series of widely attended live
events; and CURE® magazine, which reaches over 1
million readers. CURE Media Group is part of the Cranbury, New
Jersey-based MJH Associates Inc. family of businesses, which includes
the acclaimed OncLive® (
platform of resources for the practicing oncologist. For more
information, visit

View Comments and Join the Discussion!